Healios K.K. (FRA:6VX)

Market Cap	190.15M
Revenue (ttm)	558.64K
Net Income (ttm)	-22.40M
Shares Out	n/a
EPS (ttm)	-0.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5
Average Volume	309
Open	1.550
Previous Close	1.440
Day's Range	1.550 - 1.560
52-Week Range	0.935 - 4.040
Beta	n/a
RSI	32.56
Earnings Date	Feb 16, 2026

About Healios K.K.

Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company develops HLCM051, which is preparing for phase 3 clinical trial, as well as preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is in phase 2/3 and phase 3 clinical trial to treat ischemic stroke; and HLCM051, which is in phase 2 clinical trial to treat trauma. It also develops HLCR011, which is in phase 1/2 clinical trial f...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2011
• Employees: 65
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6VX

Financial Performance

In 2024, Healios K.K.'s revenue was 560.00 million, an increase of 362.81% compared to the previous year's 121.00 million. Losses were -4.24 billion, 10.8% more than in 2023.

Financial numbers in JPY